Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication for the Unaudited Financial Results for the quarter ended June 30, 2025.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience has submitted copies of the newspaper advertisement published in Financial Express and Loksatta on August 14, 2025, containing extracts of its standalone unaudited financial results for Q1 FY26. Revenue from operations stood at ₹1,450.74 million, down from ₹1,606.26 million in the same quarter last year (~9.7% YoY decline). Net profit after tax came in at ₹347.90 million versus ₹446.44 million in Q1 FY25, a YoY drop of about 22%. Basic and diluted EPS was ₹4.32, compared to ₹5.54 a year ago. The results were approved by the Board on August 13, 2025, and the statutory auditors have carried out a limited review.
The filing is a routine regulatory disclosure (newspaper publication of results), but the underlying numbers show a clear YoY and sequential decline in both revenue and profit, which may put pressure on the stock in the near term. Shareholders should note the weakness in Q1 performance, even though other equity has grown to ₹10,152.39 million.